Eton Pharmaceuticals, Inc. (NASDAQ:ETON - Free Report) - Research analysts at B. Riley lifted their Q1 2025 EPS estimates for shares of Eton Pharmaceuticals in a report issued on Sunday, April 27th. B. Riley analyst M. El-Saadi now forecasts that the company will earn $0.13 per share for the quarter, up from their prior estimate of $0.06. B. Riley has a "Buy" rating and a $24.00 price target on the stock. The consensus estimate for Eton Pharmaceuticals' current full-year earnings is ($0.14) per share. B. Riley also issued estimates for Eton Pharmaceuticals' Q2 2025 earnings at $0.06 EPS, Q3 2025 earnings at $0.11 EPS, FY2025 earnings at $0.64 EPS, FY2026 earnings at $1.48 EPS, FY2027 earnings at $1.86 EPS, FY2028 earnings at $2.23 EPS and FY2029 earnings at $2.46 EPS.
Eton Pharmaceuticals (NASDAQ:ETON - Get Free Report) last released its quarterly earnings results on Tuesday, March 18th. The company reported ($0.02) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.02). Eton Pharmaceuticals had a negative net margin of 15.81% and a negative return on equity of 36.29%. The business had revenue of $11.65 million during the quarter, compared to analyst estimates of $10.53 million.
A number of other equities analysts also recently commented on ETON. Craig Hallum lifted their target price on Eton Pharmaceuticals from $23.00 to $26.00 and gave the company a "buy" rating in a research note on Wednesday, March 19th. HC Wainwright reissued a "buy" rating and set a $33.00 price target on shares of Eton Pharmaceuticals in a report on Wednesday, March 19th.
Read Our Latest Research Report on ETON
Eton Pharmaceuticals Stock Down 2.6 %
NASDAQ:ETON traded down $0.46 during trading hours on Wednesday, reaching $16.89. 76,579 shares of the stock were exchanged, compared to its average volume of 180,788. Eton Pharmaceuticals has a 52 week low of $3.18 and a 52 week high of $18.41. The stock has a market capitalization of $452.82 million, a P/E ratio of -76.80 and a beta of 1.22. The firm has a 50 day simple moving average of $14.28 and a 200-day simple moving average of $13.32.
Institutional Trading of Eton Pharmaceuticals
Several institutional investors have recently modified their holdings of the company. Baader Bank Aktiengesellschaft acquired a new stake in Eton Pharmaceuticals in the 4th quarter valued at about $373,000. Jane Street Group LLC acquired a new position in shares of Eton Pharmaceuticals in the 3rd quarter valued at $90,000. Geode Capital Management LLC increased its stake in Eton Pharmaceuticals by 13.5% in the 3rd quarter. Geode Capital Management LLC now owns 272,696 shares of the company's stock worth $1,637,000 after purchasing an additional 32,365 shares in the last quarter. Raymond James Financial Inc. acquired a new stake in Eton Pharmaceuticals during the 4th quarter worth about $147,000. Finally, Anchor Capital Advisors LLC purchased a new stake in Eton Pharmaceuticals during the fourth quarter valued at about $805,000. Institutional investors and hedge funds own 27.86% of the company's stock.
About Eton Pharmaceuticals
(
Get Free Report)
Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1.
Recommended Stories

Before you consider Eton Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eton Pharmaceuticals wasn't on the list.
While Eton Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.